Skip to main content
. 2020 Aug 11;11:494. doi: 10.3389/fendo.2020.00494

Table 1.

Baseline demographic and clinical characteristics of participants according to the treatments.

Variables Placebo (n = 51) BC (n = 51) p-value
Age (years) 51 ± 11 53 ± 9 0.43
Weight (Kg) 80 ± 11 80 ± 12 0.94
BMI (Kg/m2) 29 ± 4 29 ± 3 0.86
WC (cm) 97 ± 8 99 ± 10 0.29
HC (cm) 107 ± 7 105 ± 7 0.30
FM (Kg) 25 ± 8 25 ± 7 0.80
SBP (mmHg) 113 ± 17 112 ± 14 0.97
DBP (mmHg) 71 ± 14 73 ± 11 0.70
CAP score (dB/m) 285 ± 40 294 ± 39 0.27
IQR 11 ± 6 11 ± 5 0.95
Stiffness (kPa) 5.3 ± 1.4 4.9 ± 1.3 0.15
IQR 14 ± 5 14 ± 7 0.53
Glucose (mg/dL) 92 ± 8 93 ± 8 0.74
Insulin (mU/L) 9.9 ± 4 10 ± 5 0.84
HOMA-IR 2.3 ± 1.0 2.3 ± 1.2 0.74
TC (mg/dL) 196 ± 39 193 ± 39 0.66
TG (mg/dL) 115 ± 48 107 ± 53 0.42
HDL-C (mg/dL) 51 ± 13 53 ± 12 0.48
LDL-C (mg/dL) 122 ± 34 118 ± 34 0.60
Non-HDL-C (mg/dL) 145 ± 36 140 ± 39 0.49
AST (IU/L) 23 ± 15 21 ± 6 0.23
ALT (IU/L) 32 ± 27 23 ± 12 0.06
γGT (UI/L) 27 ± 20 25 ± 17 0.59
Creatinine (mg/dL) 0.82 ± 0.1 0.83 ± 0.2 0.80
Uric Acid (mg/dL) 5.1 ± 1.1 5.2 ± 1.2 0.70
Total bilirubin (mg/dL) 0.61 ± 0.3 0.62 ± 0.3 0.90
Prevalence
Gender (Female,%) 45 43 1
Menopause (%) 70 68 1
Smokers (%) 12 24 0.19
Obesity (%) 41 33 0.77
MS (%) 31 22 0.37
Hypertension (%) 35 37 1
Hyperlipidemia (%) 57 49 0.55
Antihypertensive drugs (%) 29 31 1
Lipid-lowering agents (%) 10 18 0.38
Antiplatelet agents (%) 6 10 0.71
Liver steatosis S1 grade (%) 26 16 0.20
Liver steatosis S2 grade (%) 35 35 0.20
Liver steatosis S3 grade (%) 39 49
Liver Fibrosis (%) 10 6 0.71

BMI, body mass index; WC, waist circumference; HC, hip circumference; FM, fat mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAP, controlled attenuation parameter; IQR, interquartile range; HOMA-IR, homeostatic model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma glutamyltransferase.